Management of bone loss induced by aromatase inhibitors.
Aromatase inhibitors are quickly becoming standard adjuvant endocrine therapy for hormone-receptor positive breast cancer, either upfront or in sequence after tamoxifen. As other means of estrogen-depleting therapy, decreasing bone mineral density is the major side effect of this treatment. As increase in fracture incidence have already been reported in most major trials of aromatase inhibitors. Bisphosphonates are used to treat this cancer-treatment induced bone loss, the available data is reviewed here.
Gnant
Michael
M
Department of Surgery-Medical, University of Vienna, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. michael.gnant@meduniwien.ac.at
D047072:Aromatase Inhibitors / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000139:chemically induced* / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans
D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates